UPDATE 2-Ipsen ups margin goal, diabetes drug hits test target

* Q3 sales up 7.8 pct, drug sales up 9.4 at constant rates

* Increases margin goal to 17-17.5 pct from around 14 pct

* Partner Roche says diabetes drug meets Phase III goal

* Dysport launched in U.S. for spasm in neck muscles

* Shares rise 6.32 percent

(Adds CEO comment, shares, detail)

By Caroline Jacobs

PARIS, Oct 29 (Reuters) - French drugmaker Ipsen (IPN.PA) said it had positive trial data on a potential blockbuster diabetes drug with Swiss partner Roche and had launched its treatment for neck spasms in the United States.

Ipsen on Wednesday raised its full-year operating margin due to royalties from a drug partnership deal after saying its third-quarter sales grew 7.3 percent.